CEO Executive AssistantInnovation and R&D are among the most strategically important investments a manufacturing CEO oversees. They are also among the most difficult to delegate well. The challenge is not that CEOs should be uninvolved in innovation strategy; they should. The challenge is that many manufacturing CEOs remain too involved in R&D at the wrong level: reviewing individual project timelines, weighing in on specific material choices, or personally adjudicating disputes between engineering teams.
This level of involvement does not accelerate innovation. It slows it. R&D organizations that must wait for CEO input on operational decisions lose momentum. Engineers who feel second-guessed by executive intervention lose confidence. And CEOs who are managing project details are not managing the portfolio-level questions that only they can answer.
This article provides a framework for manufacturing CEOs who want to lead R&D strategy without running R&D operations.
The CEO’s Strategic Role in Innovation and R&D
Your role in innovation and R&D is portfolio-level and investment-level, not project-level or technical-level.
Specifically, you own four things:
Innovation Strategy Direction: Deciding which innovation domains align with the company’s competitive strategy and which do not. Are you investing in materials innovation, process automation, sustainability-driven product redesign, digital product integration, or platform expansion? These directional choices belong to you because they connect R&D investment to the company’s market positioning and capital allocation priorities.
Investment Envelope Approval: Setting and approving the annual R&D investment budget as a percentage of revenue and allocating it across innovation horizons. Stage-gate investment decisions above defined thresholds also belong to you.
External Innovation Relationships: Managing strategic relationships with key university research partners, government innovation agencies, and industry consortia where CEO-level engagement signals organizational commitment.
Cultural Signal-Setting: Demonstrating, through visible behaviors and decisions, that the organization treats innovation failure as learning and not as cause for punishment. This cultural signal cannot be delegated; it must come from the top.
Everything below these four areas belongs to your delegated R&D leadership structure.
Building the R&D Leadership Structure
The Chief Technology Officer or VP of R&D
The operational owner of your innovation and R&D function is your Chief Technology Officer, Chief Innovation Officer, or VP of Research and Development. This leader owns the end-to-end R&D portfolio: project selection within the approved budget, team leadership, technical direction, stage-gate management, intellectual property strategy, and external research partnerships at the operational level.
This leader should have unilateral authority over: assigning projects to engineering teams, approving project scope changes within defined budget parameters, determining technical approaches and methodologies, managing vendor and supplier relationships for R&D activities, and making go/no-go recommendations on individual projects within their portfolio authority.
They bring decisions to you only when: a project requires investment above their approved authority level, a project scope change materially affects the company’s strategic direction, an external partnership opportunity requires CEO relationship engagement, or a project is proposed for termination with significant sunk costs.
Outside these triggers, your CTO manages the R&D portfolio independently.
The Portfolio Structure Below the CTO
Your CTO typically leads through a team of technical program managers, research directors, and engineering leads organized around innovation domains or product lines. The specific structure depends on the breadth of your product portfolio, but the principle is consistent: each major innovation area should have a named technical leader with clear ownership and a defined resource allocation.
These leaders report to the CTO and do not have direct CEO access for operational decisions. If technical leads are regularly escalating to you, your CTO’s delegation structure needs strengthening.
Innovation Portfolio Management: The Horizon Framework
One of the most valuable frameworks for manufacturing R&D portfolio delegation is the three-horizon model originally developed by McKinsey. It organizes innovation investment into three categories:
Horizon 1 (Core Innovation): Incremental improvements to existing products and processes. Cost reduction, quality improvement, manufacturing efficiency gains, and minor product enhancements fall here. These projects have defined ROI expectations and relatively short development cycles.
Horizon 2 (Adjacent Innovation): Products and capabilities that extend the company’s existing business into new markets or applications. These require higher investment, longer time horizons, and higher uncertainty tolerance.
Horizon 3 (Transformational Innovation): Exploratory research into technologies or markets that could reshape the company’s business model over a five to ten year horizon. These carry the highest uncertainty and the longest payback periods.
The CEO’s portfolio role is determining how to allocate R&D investment across these three horizons, setting the balance that reflects the company’s strategic position and competitive context. A company defending an established market position might weight investment heavily toward Horizon 1. A company seeking to shift market position needs meaningful Horizon 2 and 3 investment.
Your CTO manages individual projects within each horizon against the allocation you have approved. They do not need your involvement in individual project management.
Stage-Gate Delegation: When to Involve the CEO
Stage-gate processes control how R&D projects move from concept through development to commercialization. Each gate involves a review of project progress against predefined criteria before investment continues to the next stage.
Defining CEO Gate Involvement
For Horizon 1 projects, your CTO makes all stage-gate decisions independently. These are improvements to existing products with well-understood risk profiles; they do not warrant CEO gate reviews.
For Horizon 2 projects, establish a CEO gate review at the transition from concept validation to development investment. This is the gate where investment commitment escalates significantly. You review the commercial case, the investment requirement, and the strategic fit. Your CTO reviews the technical feasibility and team readiness.
For Horizon 3 projects, CEO involvement at multiple gates is appropriate given the transformational stakes and the higher uncertainty. You do not review technical details; you review the strategic thesis and the organizational commitment required.
Document these gate participation expectations in your R&D governance framework. Consistent application of the framework prevents ad hoc escalation requests for projects that should be handled below CEO level.
Delegating External Innovation Partnerships
Manufacturing R&D increasingly involves external partners: universities, national laboratories, startups, joint industry research consortia, and government innovation programs. Managing these relationships requires a clear delegation structure.
University and Research Institution Relationships
Your CTO manages operational relationships with university research partners: defining research scopes, managing grant or contract agreements, receiving research outputs, and coordinating IP assignment. You maintain the senior relationship with the university’s president or provost for major research partnerships, appearing at annual strategic reviews and signing formal partnership agreements.
Startup Collaboration and Technology Scouting
Designate a Technology Scouting function within your CTO’s organization. This team monitors emerging technology companies, academic spin-outs, and startup ecosystems for capabilities relevant to your innovation agenda. They bring vetted opportunities to the CTO for evaluation and to you only when an opportunity involves a significant strategic investment, acquisition consideration, or partnership commitment.
Your role in startup collaboration is not to identify startups. It is to create the organizational conditions for your technology scouting team to find and evaluate them efficiently, and to make the strategic investment decisions when opportunities meet defined criteria.
For a complementary perspective on workforce development as an enabler of innovation capacity, see the manufacturing workforce delegation framework.
Intellectual Property Strategy Delegation
Intellectual property is among the most valuable outputs of manufacturing R&D. IP strategy, covering patent filing decisions, trade secret management, licensing opportunities, and IP enforcement, requires structured delegation to avoid both gaps and duplicative CEO involvement.
IP Decision Authority
Your General Counsel owns IP strategy and enforcement at the organizational policy level. Your CTO owns the interface between R&D outputs and IP strategy: identifying patentable innovations, managing the disclosure review process with the legal team, and making recommendations on filing priorities.
The CEO approves: IP licensing agreements above defined revenue thresholds, IP litigation decisions involving significant financial exposure, and IP strategy decisions that affect the company’s competitive positioning in material ways.
Routine patent filings, defensive publications, and trade secret designations run through the CTO and General Counsel without CEO involvement. Your CTO provides a quarterly IP portfolio summary covering filing activity, new grants, and any enforcement situations.
Connecting R&D to Commercial Outcomes
One of the most common failure modes in manufacturing R&D is the disconnection between innovation pipeline and commercial deployment. Projects that complete development but fail to reach market, or that reach market without adequate commercial preparation, represent wasted investment.
The R&D to Commercial Handoff
Designate a formal stage-gate at the transition from development to commercialization. At this gate, your CTO and Chief Commercial Officer jointly present to the CEO (for Horizon 2 and 3 projects) or to the COO (for Horizon 1 projects). The gate review covers technical readiness, commercial preparation, manufacturing scale-up plan, and go-to-market strategy.
This joint review ensures that commercial considerations are embedded in the handoff rather than addressed after launch. It also provides an organizational forcing function that surfaces disconnects between R&D assumptions and commercial reality before they become market failures.
For detailed structures around new product delegation, the manufacturing new product delegation framework provides stage-gate governance models applicable across product development categories.
Measuring R&D Performance
Your strategic oversight of R&D centers on portfolio-level performance metrics reviewed quarterly:
R&D Investment as Percentage of Revenue: Track this against industry benchmarks and your own strategic targets. It is a leading indicator of innovation competitiveness.
Innovation Pipeline Value: Total estimated commercial value of projects in development across all three horizons. This metric tells you whether your current pipeline can generate future growth.
Time from Concept to Commercial Launch: Average development cycle time across Horizon 1 and 2 projects. Trends in this metric indicate the efficiency of your R&D organization.
New Product Revenue Contribution: Revenue from products launched within the last three years as a percentage of total revenue. This is the ultimate lagging indicator of R&D effectiveness.
IP Portfolio Growth Rate: New patents filed and granted annually. This is a proxy metric for the volume of protectable innovation the organization is generating.
Research from the National Association of Manufacturers shows that manufacturing companies investing more than four percent of revenue in R&D consistently outperform industry peers on revenue growth and gross margin over five-year periods. The full NAM manufacturing research data is available at nam.org.
Conclusion
Innovation and R&D are too important to be left unmanaged and too technically complex to be managed by the CEO at the operational level. The manufacturing CEOs who build the strongest innovation track records do so by defining the strategic direction, setting the investment allocation, building the governance structure, and then trusting a capable CTO to run the portfolio.
Your role is to ask the right portfolio questions: Are we investing in the right innovation horizons? Are our largest bets commercially connected? Is our IP strategy protecting our most valuable innovations? Is our R&D organization attracting the engineering talent we need?
Those questions belong to you. The answers come from the organization you have built and the delegation structure you have put in place. Focus on the questions, not the project timelines.
Related Reading
For further context, explore How Manufacturing CEOs Delegate Capital Expenditure Decisions and How Manufacturing CEOs Delegate Continuous Improvement Programs.